Agilent Technologies Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Agilent Technologies Inc trades at $148.68 (market cap $42.22B), while Direxion Daily S&P 500 Bull 3X Shares trades at $294.67. The key difference: Agilent Technologies Inc pays a 0.68% dividend while Direxion Daily S&P 500 Bull 3X Shares pays none, and Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Agilent Technologies Inc nearer its low. Which is the better fit depends on your goals.
| A | SPXL | |
|---|---|---|
Market Cap | $42.22B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $157.20 | $296.39 |
52-Week Low | $110.24 | $170.20 |
Enterprise Value | $43.77B | — |
Dividend Yield | 0.68% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $148.72, up 1.88% with strong analyst support (77.5% buy ratings). The stock shows bullish technical momentum above key support levels, supported by consistent revenue around $6.9B and robust profitability with 19.55% net margins. Recent FDA approvals for diagnostic tests and the Biocare Medical acquisition enhance growth prospects in biopharma markets.
Outlook remains positive with a $154.90 consensus price target offering 4% upside, though high P/E of 30.02 poses valuation risk. Key catalysts include Q2 2026 earnings due August 26 and AI-driven lab expansion, while overbought RSI levels near 92 suggest near-term consolidation potential.
SPXL trades at $295.71, down 0.16% with a bullish technical outlook supported by moving averages. The stock shows strong momentum indicators with ADX signaling trend strength while RSI levels suggest potential overbought conditions. Recent news highlights S&P 500 reaching record highs with JPMorgan raising its 2026 target to 8,000, citing AI-driven earnings strength and corporate performance.
The leveraged ETF benefits from strong market momentum but faces valuation concerns with the S&P 500 at historically high Shiller P/E ratios. Key risks include market volatility ahead of inflation reports and potential profit-taking near resistance levels. The AI investment theme provides growth catalysts, though elevated valuations warrant caution for new positions.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →